<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03969654</url>
  </required_header>
  <id_info>
    <org_study_id>CMU2018-34K</org_study_id>
    <nct_id>NCT03969654</nct_id>
  </id_info>
  <brief_title>ROSA Total Knee Post Market Study</brief_title>
  <official_title>ROSA Total Knee Post Market Study: Prospective Multicenter U.S. Study of the ROSA Total Knee System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zimmer Biomet</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zimmer Biomet</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, multicenter clinical study designed to facilitate the collection and
      evaluation of workflow efficiency, patient pain and function, and adverse event data. This
      clinical study will include Persona, NexGen, and Vanguard product families using the ROSA
      Total Knee Robotic System or conventional instrumentation. The primary objective of this
      study is to collect and compare clinical and surgical data using the commercially available
      ROSA Total Knee robotic instrumentation and conventional instrumentation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to collect and compare clinical outcomes data using
      the commercially available ROSA Total Knee robotic instrumentation and conventional
      instrumentation.The assessments will include:Planned vs actual component positioning,
      workflow efficiency, patient safety based on incidence and frequency of adverse events, and
      clinical performance measured by overall pain and function, quality of life data, and
      radiographic parameters.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Performance</measure>
    <time_frame>1 year</time_frame>
    <description>EQ-5D Questionnaire: A questionnaire completed by the Patient and assesses his/her General health Status. The EQ5D is used to derive a Quality of life index used for health economics considerations.
Oxford Knee Score: The Oxford Knee Score is a patient completed 12 question metric to rate a patient's knee pain and function using an ordinal 0 - 4 point scale. The total score is obtained by calculating the sum of the 12 items. The minimum score is 0 and the maximum score is 48 points.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Workflow Efficiency</measure>
    <time_frame>1 year</time_frame>
    <description>Intraoperative questionnaire detailing surgical and OR efficiencies.
Operative Time
Tourniquet Time
Personnel involved/present in OR
Knee Alignment Values</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Knee Pain</condition>
  <condition>Chronic Osteoarthritis</condition>
  <condition>Avascular Necrosis of the Femoral Condyle</condition>
  <condition>Moderate Varus, Valgus or Flexion Deformities</condition>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Robotic Assisted TKA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Robotic Assisted TKA</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional TKA</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional TKA</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PERSONA Total Knee</intervention_name>
    <description>Primary Total Knee Arthroplasty</description>
    <arm_group_label>Conventional TKA</arm_group_label>
    <arm_group_label>Robotic Assisted TKA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vanguard Total Knee</intervention_name>
    <description>Primary Total Knee Arthroplasty</description>
    <arm_group_label>Conventional TKA</arm_group_label>
    <arm_group_label>Robotic Assisted TKA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>NexGen Total Knee</intervention_name>
    <description>Primary Total Knee Arthroplasty</description>
    <arm_group_label>Conventional TKA</arm_group_label>
    <arm_group_label>Robotic Assisted TKA</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient is a minimum of 18 years of age

          -  Independent of study participation, patient is a candidate for commercially available
             Persona, NexGen, and Vanguard knee components implanted in accordance with product
             labeling

          -  Patient has participated in this study-related Informed Consent process

          -  Patient is willing and able to provide written Informed Consent by signing and dating
             the IRB or EC approved Informed Consent form

          -  Patient is willing and able to complete scheduled study procedures and follow-up
             evaluations

        Exclusion Criteria:

          -  Patient is currently participating in any other surgical intervention studies or pain
             management studies

          -  Patient has underwent contralateral UKA or TKA within the last 18 months

          -  Hip pathology with significant bone loss (e.g. avascular necrosis of the femoral head
             with collapse, severe dysplasia of the femoral head or the acetabulum)

          -  Hip pathology severely limiting range of motion (e.g. arthrodesis, severe contracture,
             chronic severe dislocation)

          -  Patient is pregnant or considered a member of a protected population (e.g., prisoner,
             mentally incompetent, etc.)

          -  Patient has previously received partial or total knee arthroplasty for the ipsilateral
             knee
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kacy Arnold</last_name>
    <role>Study Director</role>
    <affiliation>Zimmer Biomet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Tory Sears</last_name>
    <phone>5745260261</phone>
    <email>tory.sears@zimmerbiomet.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Vail-Summit Orthopaedics</name>
      <address>
        <city>Vail</city>
        <state>Colorado</state>
        <zip>81657</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathan Cafferky, MD</last_name>
      <phone>970-476-7220</phone>
    </contact>
    <investigator>
      <last_name>Nathan Cafferky, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>OrthoVirginia Chippenham</name>
      <address>
        <city>North Chesterfield</city>
        <state>Virginia</state>
        <zip>23225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brendan Baggot, MS</last_name>
      <phone>804-320-1339</phone>
    </contact>
    <investigator>
      <last_name>David Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Miles Birmingham, DO</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 29, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 31, 2019</study_first_posted>
  <last_update_submitted>May 22, 2020</last_update_submitted>
  <last_update_submitted_qc>May 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

